Unified Patent Court Rules Against Angelalign Feature
The court found the Torque Ridges feature violates a patent held by Align Technology Inc. within the European market.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Do you believe patent litigation between medical device companies generally harms patient access to care?
The Paris Local Division of the Unified Patent Court has ruled that Angelalign Technology Inc.'s Torque Ridges feature infringes on a patent held by Align Technology Inc. In response to the decision, the company has officially discontinued the feature across Europe.
Why it matters
The ruling forces a shift in product design for the orthodontics provider within the European region, highlighting the ongoing legal friction regarding proprietary dental technology. The company is now reviewing the decision while navigating the implications for its European operations.
Angelalign Technology Inc. has surpassed two million cumulative orthodontic cases and maintains a market capitalization of approximately US$2 billion. The company operates in 60 countries globally.
The players
Angelalign Technology Inc.
This company specializes in orthodontic clear aligners and has grown to operate across 60 countries.
Align Technology Inc.
This corporation holds the patent that was the subject of the infringement litigation in the Unified Patent Court.
Unified Patent Court
This international court provides a centralized system for litigating patent disputes across participating European nations.
The details
To address the ruling, Angelalign Technology Inc. replaced the disputed Torque Ridges feature with a new technology called Pressure Points. This alternative was launched in the European market to maintain product performance and solve clinical challenges for orthodontists.
Timeline
2003: Angelalign Technology Inc. was founded.
2021: The company became publicly listed.
September 2026: Pressure Points launched in the European market.
October 16, 2026: The Unified Patent Court issued the patent infringement ruling.
The Tech Race
The ruling follows the procedural framework established by the Unified Patent Court Agreement for adjudicating cross-border IP disputes. This decision reflects the increasing complexity of international patent enforcement as biotech companies compete to innovate within the orthodontic aligner market.
Customers in Spain, the UK, the Americas, and Asia will see no changes to their treatment or product availability as those regions are unaffected by the ruling. European patients will transition to the Pressure Points system, which is designed to maintain clinical efficacy.
The takeaway
Companies operating in the European market must ensure their proprietary features align with the strict patent standards enforced by the Unified Patent Court. This case underscores the importance of proactive IP management when scaling medical technologies across multiple international jurisdictions.
Further reading
For more on industry developments, visit the Biotech section.
More information
For official details, see the Angelalign company information.
Live Poll
Do you believe patent litigation between medical device companies generally harms patient access to care?
